IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court
Carlsbad, CA 92010
United States
760-931-9200
http://www.ionispharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees547

Key Executives

NameTitlePayExercisedYear Born
Dr. Stanley T. CrookeFounder, Exec. Chairman, CEO & Pres2.06M3.57M1945
Dr. Brett P. MoniaFounder, COO and Sr. VP of Antisense Drug Discovery & Translational Medicine786.67kN/A1961
Ms. Elizabeth L. HougenCFO & Sr. VP of Fin.735.75k319.89k1962
Dr. Richard S. Geary Ph.D.Sr. VP of Devel.N/AN/A1958
Ms. B. Lynne ParshallSr. Strategic Advisor & Director1.54M808.66k1954
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Corporate Governance

Ionis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2018 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.